Vaccination Uptake (VAX) in PD
Status: | Active, not recruiting |
---|---|
Conditions: | Parkinsons Disease |
Therapuetic Areas: | Neurology |
Healthy: | No |
Age Range: | 65 - Any |
Updated: | 1/17/2019 |
Start Date: | September 2016 |
End Date: | August 2019 |
Vaccination Uptake in Parkinson's Disease
This is a study to see whether participation in the Edmond J. Safra Interdisciplinary Home
Visit Program for Advanced Parkinson's (HVP) increases the rate of age-appropriate
vaccinations in people with advanced Parkinson's Disease (PD) and related disorders. This
study will evaluate the impact of the HVP on the rate of common illnesses such as flu and
pneumonia in patients with advanced PD and related disorders over the course of one year.
As there is currently no data available on the baseline rate of vaccinations in either
homebound or less disabled PD populations, investigators will seek to establish the baseline
rate of vaccinations, barriers to getting vaccinated, and baseline healthcare utilization in
these populations by piloting (Phase 1) and then implementing (Phase 2) a survey via
telephone interviews. Investigators will then test feasibility of offering influenza and
pneumococcal vaccinations, as appropriate, to the homebound individuals in our HVP cohort
(Phase 3), and will compare their pre- and post-intervention rates of both outpatient and
acute healthcare utilization and self-reported illness.
Visit Program for Advanced Parkinson's (HVP) increases the rate of age-appropriate
vaccinations in people with advanced Parkinson's Disease (PD) and related disorders. This
study will evaluate the impact of the HVP on the rate of common illnesses such as flu and
pneumonia in patients with advanced PD and related disorders over the course of one year.
As there is currently no data available on the baseline rate of vaccinations in either
homebound or less disabled PD populations, investigators will seek to establish the baseline
rate of vaccinations, barriers to getting vaccinated, and baseline healthcare utilization in
these populations by piloting (Phase 1) and then implementing (Phase 2) a survey via
telephone interviews. Investigators will then test feasibility of offering influenza and
pneumococcal vaccinations, as appropriate, to the homebound individuals in our HVP cohort
(Phase 3), and will compare their pre- and post-intervention rates of both outpatient and
acute healthcare utilization and self-reported illness.
Inclusion Criteria:
Phase 1:
- Diagnosed with idiopathic Parkinson's disease (a chronic, slowly-progressive
neurological disorder), or related disorders including Dementia with Lewy Bodies,
Multiple System Atrophy, Progressive Supranuclear Palsy, or Corticobasal Syndrome.
Phase 2:
- Subjects will be those diagnosed with idiopathic Parkinson's disease (a chronic,
slowly-progressive neurological disorder), or related disorders including Dementia
with Lewy Bodies, Multiple System Atrophy, Progressive Supranuclear Palsy, or
Corticobasal Syndrome.
- Each subject must either 1) be willing and able to provide verbal, informed consent
for the study, and for whom capacity to consent will be assessed using the questions
below, or 2) if unable to provide informed consent due to lack of capacity, a
caregiver is able to provide informed consent and the subject provides assent to
participation.
Phase 3:
- Diagnosed with idiopathic Parkinson's disease (a chronic, slowly-progressive
neurological disorder), or related disorders including Dementia with Lewy Bodies,
Multiple System Atrophy, Progressive Supranuclear Palsy, or Corticobasal Syndrome.
- Each subject must either 1) be willing and able to provide written, informed consent
for the study, and for whom capacity to consent will be assessed using the questions
below, or 2) if unable to provide informed consent due to lack of capacity, a
caregiver is able to provide informed consent and the subject provides assent to
participation.
Subjects have one or more of the following criteria:
- Fluctuation
- Multi-morbidity
- Mismanages medication
- Cognitive impairment
- High risk for re-hospitalization
- High risk for nursing facility admission
- Suspected elder abuse
- Recent history of increased falls in home
- Caregiver burnout suspected
- Ability to participate in the research study as deemed by the Principal Investigator.
Exclusion Criteria:
- Diagnosis of another neurodegenerative disease or other major central nervous system
disorder.
Subjects with severe hearing impairment or speech dysfunction that would preclude pa
-Subjects with active psychosis or exhibiting symptoms of a severe psychiatric disorder.
We found this trial at
1
site
550 1st Ave
New York, New York 10016
New York, New York 10016
(212) 263-7300
Principal Investigator: Jori Fleisher, MD
Phone: 646-501-4871
New York University School of Medicine NYU School of Medicine has a proud history that...
Click here to add this to my saved trials